Stock KERYX BIOPHARMACEUTICALS
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Highlights Keryx Biopharmaceuticals

Equities

US4925151015

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc. and Averoa SAS Enter into License Agreement
CI
Keryx Biopharmaceuticals, Inc. Announces Settlement of Auryxia Patent Litigation with Panion & Bf Biotech Inc
CI
Keryx Biopharmaceuticals, Inc., and Panion & BF Biotech, Inc Enters into License Agreement with Par Pharmaceutical, Inc
CI
Akebia Therapeutics Inc. (‘Akebia’) completed the acquisition of Keryx Biopharmaceuticals Inc. (‘Keryx’) from Baupost Group Securities LLC (‘Baupost’), Abrams Capital LLC, The Vanguard Group Inc. and other shareholders in a merger of equals transaction.
CI
Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Therapeutics
GL
Keryx Biopharmaceuticals : ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics
PU
ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics
GL
Keryx Biopharmaceuticals, Inc. Reports Unaudited and Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018
CI
Keryx Biopharmaceuticals, Inc. Reports Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2018
CI
Akebia Therapeutics, Inc and Keryx Biopharmaceuticals, Inc Merger Call
FA
Akebia Therapeutics Inc. entered into an agreement acquire Keryx Biopharmaceuticals Inc. from Baupost Group Securities LLC, Abrams Capital LLC, The Vanguard Group Inc. and other shareholders for approximately $480 million in a merger of equals transaction.
CI
Keryx Biopharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018
CI
Keryx Biopharmaceuticals, Inc. Provides Preliminary Revenue Results for the First Quarter 2018
CI
Keryx Biopharmaceuticals, Inc. Announces Publication of Data from the Phase 3 Trial of Auryxia® (ferric citrate) for Iron Deficiency Anemia in Patients with Chronic Kidney Disease, Not on Dialysis, in the American Journal of Hematology
CI
Keryx Biopharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended of December 31, 2017
CI
BioVectra and Keryx Biopharmaceuticals Enter Agreement for Ferric Citrate Production Expansion
CI
Keryx Biopharmaceuticals and BioVectra Enter into Product Manufacture and Supply and Facility Construction Agreement
CI
Keryx Announces the Second Approval for Auryxia to Treat Iron Deficiency Anemia in Patients with Chronic Kidney Disease
CI
Keryx Biopharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017
CI
Keryx Biopharmaceuticals Announces Presentation of Real World Dialysis Data of Auryxia at ASN’s 2017 Kidney Week
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Keryx Biopharmaceuticals
  5. Highlights